Profile data is unavailable for this security.
About the company
Chengdu Olymvax Biopharmaceuticals Inc is a China-based biopharmaceutical company mainly engaged in the research, development, production and sales of human vaccines. The Company's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The Company's main customers are center for disease control and prevention (CDC) customers.
- Revenue in CNY (TTM)530.47m
- Net income in CNY-8.70m
- Incorporated2009
- Employees471.00
- LocationChengdu Olymvax Biopharmaceuticals IncNo. 99 Tianxin Road, High-tech ZoneCHENGDU 611731ChinaCHN
- Phone+86 2 869361198
- Fax+86 2 869361100
- Websitehttps://www.olymvax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Fudan Forward S&T Co Ltd | 638.98m | -15.28m | 4.16bn | 1.36k | -- | 5.38 | -- | 6.50 | -0.0222 | -0.0222 | 0.9345 | 1.13 | 0.3799 | 0.6476 | 8.53 | 468,807.20 | -0.9863 | -0.8781 | -1.68 | -1.53 | 36.63 | 43.22 | -2.60 | -1.85 | 0.413 | -2.40 | 0.3319 | -- | -13.86 | -7.58 | 196.17 | -32.57 | -13.88 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 530.47m | -8.70m | 4.31bn | 471.00 | -- | 4.73 | -- | 8.12 | -0.0219 | -0.0219 | 1.31 | 2.24 | 0.3301 | 0.3685 | 1.04 | 1,126,255.00 | -0.9143 | 3.17 | -1.28 | 4.68 | 94.19 | 93.00 | -2.77 | 7.44 | 1.67 | -0.5392 | 0.2915 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Tibet Weixinkang Pharmaceutical Co Ltd | 1.26bn | 247.04m | 4.42bn | 701.00 | 17.90 | 2.98 | -- | 3.52 | 0.5677 | 0.5677 | 2.89 | 3.41 | 0.6778 | 16.41 | 5.56 | 1,791,483.00 | 13.33 | 8.20 | 17.01 | 11.13 | 53.45 | 50.20 | 19.67 | 11.53 | 3.27 | -- | 0.0075 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Shanghai New World Co Ltd | 1.13bn | 45.48m | 4.49bn | 1.20k | 98.72 | 1.06 | -- | 3.96 | 0.0703 | 0.0703 | 1.75 | 6.53 | 0.201 | 3.94 | 10.25 | 942,735.10 | 0.7905 | 0.5242 | 1.05 | 0.7249 | 38.77 | 33.70 | 3.93 | 2.71 | 1.57 | -- | 0.1158 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
| Yabao Pharmaceutical Group Co Ltd | 2.83bn | 220.70m | 4.49bn | 4.14k | 20.41 | 1.52 | -- | 1.59 | 0.3057 | 0.3057 | 3.86 | 4.10 | 0.7389 | 3.51 | 6.66 | 683,686.80 | 5.11 | 2.82 | 6.38 | 3.97 | 52.85 | 59.20 | 6.92 | 4.19 | 2.04 | 129.51 | 0.0313 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 713.75m | 233.79m | 4.51bn | 1.14k | 19.07 | 2.02 | -- | 6.32 | 1.19 | 1.19 | 3.63 | 11.26 | 0.2367 | 0.7194 | 7.25 | 624,455.80 | 7.75 | 10.04 | 9.09 | 11.63 | 80.01 | 83.66 | 32.75 | 28.29 | 3.48 | -- | 0.2098 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
| Lionco Pharmaceutical Group Co Ltd | 277.20m | -101.80m | 4.53bn | 475.00 | -- | 5.29 | -- | 16.34 | -0.144 | -0.144 | 0.3828 | 1.19 | 0.1843 | 2.48 | 4.41 | 583,571.30 | -6.77 | 0.7396 | -7.85 | 0.9562 | 41.77 | 80.88 | -36.73 | 2.08 | 4.94 | -4.74 | 0.2409 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
Data as of Nov 06 2024. Currency figures normalised to Chengdu Olymvax Biopharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY
13.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2024 | 31.23m | 10.84% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 2.73m | 0.95% |
| Harfor Fund Management Co., Ltd.as of 30 Jun 2024 | 1.50m | 0.52% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 495.98k | 0.17% |
| Golden Eagle Asset Management Co., Ltd.as of 30 Jun 2024 | 454.39k | 0.16% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 359.48k | 0.13% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 292.13k | 0.10% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 262.28k | 0.09% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 202.79k | 0.07% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 192.87k | 0.07% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
